Product Description
Polyclonal avian immunoglobulin IgY containing specific IgY against E. coli F18ab and S. typhimurium
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: IgNova
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| IGN-ES001-CR01 | N/A |
Completed |
Chronic Pain|Myofascial Pain Syndromes|Fibromyalgia |
2017-11-30 |
2022-12-13 |
Recent News Events
Date |
Type |
Title |
|---|